Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Infanrix hexa Co-administered with OPV in Healthy Infants
NCT01457560Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2000
- Primary completion
- Apr 2001
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis, hepatitis B (HBV), poliomyelitis, sponsored by GSK. Started Feb 2000; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT01457560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457560.